401 - Host, treatment, and disease-related risk factors for invasive fungal disease in 549 patients with newly diagnosed high-risk myeloid malignancies treated with intensive induction chemotherapy

Presenting Author(s)

• 

  Victor Kovac, MD (he/him/his)

  Fellow
  Brigham and Women's Hospital
  Boston, MA, United States

  Slides

Co-Author(s)

• AS

  Archana Sasi, MBBS

  Dana Farber Cancer Institute
  Boston, Massachusetts, United States
• 

  Jessica S. Little, MD (she/her/hers)

  Transplant Infectious Diseases Physician
  Brigham and Women's Hospital
  Boston, MA, United States
• YL

  Yiwen Liu, MS

  Dana Farber Cancer Institute
  Boston, Massachusetts, United States
• AW

  Ann E. Woolley, MD

  Attending Physician
  Brigham and Women's Hospital
  Boston, Massachusetts, United States
• ML

  Marlise Luskin, M.D.

  Dana-Farber Cancer Institute
  Boston, Massachusetts, United States
• SS

  Shai Shimony, MD, MPH

  Dana Farber Cancer Institute
  Boston, Massachusetts, United States
• RL

  R Coleman Lindsley, MD, PhD

  Dana Farber Cancer Institute
  Boston, Massachusetts, United States
• 

  Lindsey R. Baden, MD

  Attending Physician
  Brigham and Women's Hospital
  Boston, MA, United States
• RV

  Rahul S. Vedula, MD

  Fellow
  Dana Farber Cancer Institute
  Boston, MA, United States